A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2)
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Calcitriol (Primary) ; Docetaxel (Primary) ; Dexamethasone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASCENT-2
- Sponsors Transcept Pharmaceuticals Inc
- 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 07 Jun 2022 Results (n=2028) from 4 randomized phase 3 trials (NCT00273338, NCT00988208, NCT00617669, and NCT00519285) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 May 2020 Results (n=1577) of Ascent2, Mainsail and Venice trials, inverse correlation between obesity and mortality in patients, presented at the 115th Annual Meeting of the American Urological Association